Improved pharmacokinetic monitoring of tacrolimus exposure after pediatric renal transplantation

Pediatric Transplantation

Volumn 11, Issue 4, 2007, Pages 388-393

  Lee, Martin N ^a   Butani, Lavjay ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Drug exposure; Monitoring; Pediatric; Pharmacokinetic; Steroid free; Steroids; Tacrolimus; Time concentration curve; Trough

Indexed keywords

INTERLEUKIN 2 RECEPTOR ANTIBODY; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY;

AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC ACCURACY; DOSE CALCULATION; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEMALE; GRAFT RECIPIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; TREATMENT OUTCOME;

CHILD; DRUG MONITORING; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; TACROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 34247616170     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2006.00618.x     Document Type: Article

References (23)

1. Calne R. Cyclosporine as a milestone in immunosuppression. Transplant Proc 2004 : 36 : 13S 15S.
2. Ruiz JC, Campistol JM, Grinyo JM, et al. Early cyclosporine a withdrawal in kidney-transplant recipients receiving sirolimus prevents progression of chronic pathologic allograft lesions. Transplantation 2004 : 78 : 1312 1318.
3. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR. The natural history of chronic allograft nephropathy. N Engl J Med 2003 : 349 : 2326 2333.
4. Weir MR, Blahut S, Drachenburg C, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004 : 24 : 379 386.
5. Bakker RC, Hollander AA, Mallat MJ, Bruijn JA, Paul LC, de Fijter JW. Conversion from cyclosporine to azathioprine at three months reduces the incidence of chronic allograft nephropathy. Kidney Int 2003 : 64 : 1027 1034.
6. Metcalfe MS, Jain S, Waller JR, Saunders RN, Bicknell GR, Nicholson ML. A randomized trial of mycophenolate mofetil versus azathioprine as calcineurin inhibitor sparing agents in the treatment of chronic allograft nephropathy. Transplant Proc 2002 : 34 : 1812 1814.
7. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther 1993 : 54 : 205 218.
8. Filler G, Grygas R, Mai I, et al. Pharmacokinetics of tacrolimus (FK 506) in children and adolescents with renal transplants. Nephrol Dial Transplant 1997 : 12 : 1668 1671.
9. Meier-Kriesche HU, Bonilla-Felix MA, Ferris ME, et al. A limited sampling strategy for the estimation of Neoral AUCs in pediatric patients. Pediatr Nephrol 1999 : 13 : 742 747.
10. Paydas S, Balal M, Sertdemir Y, Seyrek N, Karayaylali I. Long-term comparative results of C0 and C2 monitoring of CyA in renal transplanted patients. Ren Fail 2005 : 27 : 409 413.
11. Dominguez J, Fuenzalida D, Norambuena R, Pais E, Cortes Monroy G, Llanos R. C2 monitoring of cyclosporine in stable renal transplant patients results in lower costs and improved renal function. Transplant Proc 2005 : 37 : 1583 1585.
12. Jorgensen K, Povlsen J, Madsen S, et al. C2 (2-h) levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal-transplant patients. Nephrol Dial Transplant 2002 : 17 : 1487 1490.
13. Filler G, Webb NJ, Milford DV, et al. Four-year data after pediatric renal transplantation: A randomized trial of tacrolimus vs. cyclosporin microemulsion. Pediatr Transplant 2005 : 9 : 498 503.
14. Wong KM, Shek CC, Chau KF, Li CS. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000 : 35 : 660 666.
15. Vidhun JR, Sarwal MM. Corticosteroid avoidance in pediatric renal transplantation. Pediatr Nephrol 2005 : 20 : 418 426.
16. Schroeder TJ, Hariharan S, First MR. Relationship between cyclosporine bioavailability and clinical outcome in renal transplant recipients. Transplant Proc 1994 : 26 : 2787 2790.
17. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: Its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation 1999 : 68 : 55 62.
18. Kershner RP, Fitzsimmons WE. Relationship of FK506 whole blood concentrations and efficacy and toxicity after liver and kidney transplantation. Transplantation 1996 : 62 : 920 926.
19. Undre NA, van Hooff J, Christiaans M, et al. Low systemic exposure to tacrolimus correlates with acute rejection. Transplant Proc 1999 : 31 : 296 298.
20. Filler G, Feber J, Lepage N, Weiler G, Mai I. Universal approach to pharmacokinetic monitoring of immunosuppressive agents in children. Pediatr Transplant 2002 : 6 : 411 418.
21. Webb NJ, Stevenson PJ, Lewis MA, Postlethwaite RJ, Bradbury MG, Undre NA. Pharmacokinetics of tacrolimus in paediatric renal transplant recipients. Transplant Proc 2002 : 34 : 1948 1950.
22. Anglicheau D, Flamant M, Schlageter MH, et al. Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation. Nephrol Dial Transplant 2003 : 18 : 2409 2414.
23. Kim JS, Aviles DH, Silverstein DM, Leblanc PL, Matti Vehaskari V. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005 : 9 : 162 169.